INTRODUCTION: Our objective was to conduct an individual patient data meta-analysis (IPDMA) of the two published randomized placebo-controlled trials of mirabegron in people with neurogenic lower urinary tract dysfunction (NLUTD) due to spinal cord injury (SCI) or multiple sclerosis (MS). METHODS: We identified two randomized, placebo-controlled trials. We extracted individual patient data from the trials and evaluated two primary outcomes: change in maximum cystometric capacity and change in the patient perception of bladder condition (PPBC). We also evaluated several secondary outcomes related to urodynamic function and quality of life. We conducted three exploratory analyses to test hypotheses based on our clinical experiences with mirabegron in NLUTD. Analysis of covariance with adjustment for baseline values was used for the statistical analysis. RESULTS: Our IPDMA included 98 patients from the two trials. The results showed that mirabegron was associated with a significant improvement in maximum cystometric capacity (+41 mL, p = 0.04) and in the PPBC (-0.8, p < 0.01) compared to placebo. Secondary outcomes including peak neurogenic detrusor overactivity pressure (-20 cm H2O, p < 0.01), incontinence-QOL score (+12, p < 0.01), and 24 h pad weights (-79 g, p = 0.04) also improved significantly compared to placebo. Exploratory analyses found similar improvements in people with MS and SCI; some outcomes improved to a greater degree among people with incomplete SCI, or SCIs that were below T7. CONCLUSIONS: Our IPDMA provides evidence supporting the use of mirabegron in patients with NLUTD due to SCI or MS. Further work evaluating differential responses in people with different SCI lesion characteristics may be warranted.

Department of Surgery and Epidemiology and Biostatistics Western University London Ontario Canada

Department of Surgical Studies Ostrava University Ostrava Czech Republic

Department of Urology University Hospital Ostrava Czech Republic

Zobrazit více v PubMed

Ginsberg DA, Boone TB, Cameron AP, et al. The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: diagnosis and evaluation. J Urol. 2021;206(5):1097‐1105.

Groen J, Pannek J, Castro‐Diaz D, et al. Summary of European Association of Urology (EAU) Guidelines on Neuro‐Urology. Eur Urol. 2016;69(2):324‐333. doi:10.1016/j.eururo.2015.07.071

Madhuvrata P, Singh M, Hasafa Z, Abdel‐Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta‐analysis. Eur Urol. 2012;62(5):816‐830.

Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015;Jul 14(7):720‐732.

Madersbacher H, Mürtz G, Stöhrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013;51(6):432‐441.

Jaggi A, Nazir J, Fatoye F, et al. Drug utilization patterns and healthcare resource use and costs in patients with neurogenic bladder in the United Kingdom: a retrospective primary care database study. Neurourol Urodyn. 2019;5(10):51.

Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)‐adrenoceptor agonist, in patients with overactive bladder: results from a randomised European‐Australian phase 3 trial. Eur Urol. 2013;63(2):283‐295.

Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of Mirabegron in patients with overactive bladder. J Urol. 2012;189(4):1388‐1395.

Zhang D, Sun F, Yao H, et al. The efficacy and safety of Mirabegron for the treatment of neurogenic lower urinary tract dysfunction: a systematic review and meta‐analysis. Front Pharmacol. 2021;12:756582.

Akkoc Y. Efficacy and safety of mirabegron for treatment of neurogenic detrusor overactivity in adults with spinal cord injury or multiple sclerosis: a systematic review. Spinal Cord. 2022;60(10):854‐861.

Bapir R, Bhatti KH, Eliwa A, et al. Efficacy of overactive neurogenic bladder treatment: a systematic review of randomized controlled trials. Arch Ital  Urol Androl. 2022;94(4):492‐506.

Ventresca M, Schünemann HJ, Macbeth F, et al. Obtaining and managing data sets for individual participant data meta‐analysis: scoping review and practical guide. BMC Med Res Methodol. 2020;20(1):113.

Stewart LA, Tierney JF. To IPD or not to IPD? Eval Health Prof. 2002;25(1):76‐97.

Krhut J, Borovička V, Bílková K, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity—prospective, randomized, double‐blind, placebo‐controlled study. Neurourol Urodyn. 2018;37(7):2226‐2233.

Welk B, Hickling D, McKibbon M, Radomski S, Ethans K. A pilot randomized‐controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 20181 37(8):2810‐2817.

Ho C, Linsenmeyer T, Millis S. The reproducibility of urodynamic studies of neurogenic bladders in spinal cord injury. J Spinal Cord Med. 2000;23(4):276‐283.

Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single‐item global measure for patients with overactive bladder. Eur Urol. 2006;49(6):1079‐1086.

Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron R. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil. 2007;88(5):646‐652.

Gaus W. Interpretation of statistical significance—exploratory versus confirmative testing in clinical trials, epidemiological studies, meta‐analyses and toxicological screening (using Ginkgo biloba as an example). Clin Exp Pharmacol. 2015;5(4):182. doi:10.4172/2161-1459.1000182

Amarenco G, Sutory M, Zachoval R, et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: results from the double‐blind, randomized, active‐ and placebo‐controlled SONIC urodynamic study. Neurourol Urodyn. 2017;36(2):414‐421.

Menhaji K, Cardenas‐Trowers OO, Chang OH, Hall EF, Ringel NE, Falk KN. Anticholinergic prescribing pattern changes of urogynecology providers in response to evidence of potential dementia risk. Int Urogynecol J. 2021;32(10):2819‐2826.

Decalf VH, Huion AMJ, Benoit DF, Denys MA, Petrovic M, Everaert KCMM. Older people's preferences for side effects associated with antimuscarinic treatments of overactive bladder: a discrete‐choice experiment. Drugs Aging. 2017;34(8):615‐623.

Trbovich M, Romo T, Polk M, et al. The treatment of neurogenic lower urinary tract dysfunction in persons with spinal cord injury: an open label, pilot study of anticholinergic agent vs. mirabegron to evaluate cognitive impact and efficacy. Spinal Cord Ser Cases. 2021;7(1):50.